May-14 -

Melanoma Group

EORTC 18021 – Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma : a randomized phase III study of the EORTC Melanoma Group.

Uveal melanoma (UM) is a rare disease arising from the pigmented uveal tract of the eye, with cancerous cells spreading in 95% of patients in liver. Therefore, this EORTC trial evaluated the effectiveness of delivering treatment of fotemustine via hepatic intra-arterial (HIA) vs intra-venously (IV) in patients with liver metastases from uveal melanoma. Results showed that hepatic intra-arterial (HIA) delivery of fotemustine did not improve overall survival compared to intravenous delivery in patients with uveal melanoma.

READ MORE

Go to Top